Biology and Genetics of Adult Male Germ Cell Tumors

2006 ◽  
Vol 24 (35) ◽  
pp. 5512-5518 ◽  
Author(s):  
Jane Houldsworth ◽  
James E. Korkola ◽  
George J. Bosl ◽  
R. S. K. Chaganti

Adult male germ cell tumors (GCTs) arise by transformation of totipotent germ cells. They have the unique potential to activate molecular pathways, in part mimicking those occurring during gametogenesis and normal human development, as evidenced by the array of histopathologies observed in vivo. Recent expression profiling studies of GCTs along with advances in embryonic stem-cell research have contributed to our understanding of the underlying biology of the disease. Gain of the short arm of chromosome 12 detected in almost all adult GCTs appears to be multifunctional in germ cell tumorigenesis on the basis of the observed overexpression of genes mapped to this region involved in maintenance of pluripotency and oncogenesis. Expression signatures associated with the different histopathologies have yielded clues as to the functional mechanisms involved in GCT invasion, loss of pluripotency, and lineage differentiation. Genomic and epigenomic abnormalities that contribute to or cause these events have been identified by traditional genome analyses and continue to be revealed as genome-scanning technologies develop. Given the high sensitivity of most GCTs to cisplatin-based treatment, these tumors serve as an excellent model system for the identification of factors associated with drug resistance, including differentiation status and acquisition of genomic alterations. Overall, adult male GCTs provide a unique opportunity for the examination of functional links between transformation and pluripotency, genomic and epigenomic abnormalities and lineage differentiation, and the identification of genetic features associated with chemotherapy resistance.

2007 ◽  
Vol 47 (1) ◽  
pp. 43-55 ◽  
Author(s):  
J. E. Korkola ◽  
S. Heck ◽  
A. B. Olshen ◽  
V. E. Reuter ◽  
G. J. Bosl ◽  
...  

2011 ◽  
Author(s):  
Nirmala Jagadish ◽  
Manjunath Kustagi ◽  
Geetu Mendiratta ◽  
Ritu Kushwaha ◽  
Mukesh Bansal ◽  
...  

Author(s):  
George J. Bosl

Our knowledge about the management of men with germ cell tumors (GCTs) and its tumor biology continues to evolve. Vascular disease, metabolic syndrome, second malignant neoplasms, and hypogonadism occur after treatment for GCTs and the latency pattern resembles that seen in patients treated for Hodgkin lymphoma. Patients receiving treatment for GCTs should be informed not only of the near-term toxicity (experienced during or shortly after administration), but also the delayed and late effects of chemotherapy and the need for lifelong surveillance for all late outcomes, including late relapse. Recent data suggest that the treatment outcome of patients with intermediate-risk, poor-risk, and relapsed GCTs can be improved through multicenter trials that include the general oncology community. Finally, GCTs are a malignancy of primordial germ cells. Programmed differentiation is clinically evident in vivo and probably related to chemotherapy resistance. This biology has much clinical relevance, some of which is already in use.


Apmis ◽  
1998 ◽  
Vol 106 (1-6) ◽  
pp. 80-84 ◽  
Author(s):  
R. S. K. CHAGANTI ◽  
JANE HOULDSWORTH

2006 ◽  
Vol 66 (2) ◽  
pp. 820-827 ◽  
Author(s):  
James E. Korkola ◽  
Jane Houldsworth ◽  
Rajendrakumar S.V. Chadalavada ◽  
Adam B. Olshen ◽  
Debbie Dobrzynski ◽  
...  

2006 ◽  
pp. 221-229
Author(s):  
Jane Houldsworth ◽  
George J. Bosl ◽  
R. S. K. Chaganti

2010 ◽  
Vol 53 (10) ◽  
pp. 1006-1018 ◽  
Author(s):  
Ingo Langner ◽  
Nils Schmeißer ◽  
Birte Mester ◽  
Thomas Behrens ◽  
Andrea Gottlieb ◽  
...  

2003 ◽  
Vol 308 (1) ◽  
pp. 139-147 ◽  
Author(s):  
Henrikki Santti ◽  
Laura Mikkonen ◽  
Sirpa Hirvonen-Santti ◽  
Jorma Toppari ◽  
Olli A Jänne ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document